Search clinical trials for: Anti-PD1 antibody, nimotuzumab and capecitabine

Total 3240 results

Sun Yat-sen University
First Affiliated Hospital, Sun Yat-Sen University; The First Affiliated Hospital... and other collaborators

Withdrawn

Lenvatinib Plus PD-1 Antibody Versus Lenvtinib Alone for Advanced HCC

Hepatocellular Carcinoma

China
ABL Bio, Inc.

Recruiting

Study to Evaluate the Safety and Tolerability of ABL501, and to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ABL501 in Subjects With Any Progressive, Locally Advanced (Unresectable) or Metastatic Solid Tumors

Advanced Solid Tumor

Korea, Republic of
Shanghai Huaota Biopharmaceutical Co., Ltd.

Completed

HB0034 in Patients With Generalized Pustular Psoriasis (GPP)

Generalized Pustular Psoriasis

China
CSL Behring

Completed

Pharmacokinetics and Safety of Subcutaneous CSL324 in Healthy Japanese and White Subjects

Healthy

Australia
Shanghai Henlius Biotech
Hengenix Biotech Inc; Sanyou Biopharmaceuticals(Shanghai)Co., Ltd; Shanghai ZJ...

Withdrawn

Evaluate Safety and Pharmacokinetics of HLX70 in Healthy Adult Volunteers

COVID-19
St. Jude Children's Research Hospital
University of Wisconsin, Madison; Duke University; Children's Hospital Los Angeles and other collaborators

Completed

A Phase I Trial Of The Humanized Anti-GD2 Antibody In Children And Adolescents With Neuroblastoma, Osteosarcoma, Ewing Sarcoma and Melanoma

Melanoma | Osteosarcoma | Ewing Sarcoma | Neuroblastoma

United States
The Fourth Affiliated Hospital of Zhejiang University...

Recruiting

A Dose Escalation and Dose Expansion Clinical Study of STI-7349 in Subjects With Advanced Solid Tumors

Advanced Solid Tumor

China
Sun Yat-sen University

Not yet recruiting

Zimberelimab Plus Lenvatinib After Progression on Prior Immune Checkpoint Inhibitors for Advanced Cervical Cancer

Cervical Cancer | Cervical Carcinoma

China
Dartmouth-Hitchcock Medical Center
Sanofi; Hoffmann-La Roche

Completed

Docetaxel and Carboplatin Followed by Oral Capecitabine, Docetaxel and Radiation for Esophageal Cancer

Esophageal Neoplasms

United States
Samsung Medical Center

Completed

Phase II Study of Epirubicin, Cisplatin and Capecitabine (ECX) Versus Cisplatin and Capecitabine (CX) for Advanced Gastric Cancer (AGC)

Advanced Gastric Cancer

Korea, Republic of
The University of Texas Health Science Center at...

Terminated

AGEN1884 Plus AGEN2034 Combined With Cisplatin-Gemcitabine for Muscle-Invasive Bladder Cancer

Urinary Bladder Neoplasms

United States
ThromboGenics

Completed

A Study to Evaluate the Safety and Efficacy of THR-317 for the Treatment of Diabetic Macular Oedema (DME)

Diabetic Retinopathy | Macular Edema

Czechia, Slovakia, Hungary
Vejle Hospital

Completed

Combined Biological Treatment and Chemotherapy for Patients With Inoperable Cholangiocarcinoma

Cholangiocarcinoma

Denmark
Shanghai Jiao Tong University Affiliated Sixth...

Recruiting

Neoadjuvant Chemotherapy Combined With PD-1 + Radical Radiotherapy in Locally Advanced Cervical Cancer (PD-1)

Cervical Cancer | Radiotherapy | Neoadjuvant Chemotherapy | PD-1 Antibody

China
Technische Universität Dresden
University Hospital Schleswig-Holstein; University Hospital of Cologne; University... and other collaborators

Completed

Ofatumumab Induction and Maintenance in Elderly Patients With Poor Risk CLL in the Context of Allogeneic Transplantation

Chronic Lymphatic Leukemia

Germany
University of Athens
University of Thessaly

Completed

Steroids and Post-resuscitation Infectious (Septic) Complications

Infections | Cardiac Arrest

France, Greece
Rahul Aggarwal
Fortis Therapeutics, Inc.

Recruiting

FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer

Prostate Cancer | Metastatic Castration-resistant Prostate Cancer

United States
University of Arizona
National Cancer Institute (NCI)

Completed

Monoclonal Antibody Therapy in Treating Patients With Advanced Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Unspecified Adult Solid Tumor, Protocol Specific | Multiple Myeloma and Plasma Cell Neoplasm | Precancerous/Nonmalignant Condition

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

Inotuzumab Ozogamicin in Treating Patients With Relapsed or Refractory CD22 Positive Acute Lymphoblastic Leukemia

Recurrent Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia | CD22 Positive

United States
Fudan University

Not yet recruiting

Inosine Reverse Chemo Resistance in Triple Negative Breast Cancer

Triple-negative Breast Cancer
Frontier Biotechnologies Inc.

Recruiting

Albuvirtide and 3BNC117 as Long-Acting Maintenance Therapy in Virologically Suppressed Subjects (ABL)

HIV-1-infection

United States
AstraZeneca

Completed

A Rollover Study for Patients Who Received Tremelimumab in Other Protocols, to Allow the Patients Access to Tremelimumab Until This Agent Becomes Commercially Available or Development is Discontinued.

Melanoma | Neoplasms | Renal Cell Carcinoma | Prostatic Neoplasms | Colorectal Neoplasms | Patients Who Have/Have Had Melanoma and Other Tumors

United States, United Kingdom
GlaxoSmithKline

Completed

Iodine-131 Anti-B1 Antibody (Tositumomab and Iodine I 131 Tositumomab) for Previously Untreated, Advanced-stage, Low Grade Non-Hodgkin's Lymphoma

Lymphoma, Non-Hodgkin
Sheng-Li Xue, MD
Northern Jiangsu Province People's Hospital; The Second People's Hospital of... and other collaborators

Recruiting

Inotuzumab Ozogamicin in the Treatment of MRD+ After HSCT of ALL

Hematopoietic Stem Cell Transplantation | ALL | MRD-positive

China
GlaxoSmithKline

Completed

Study of Iodine-131 Anti-B1 Antibody for Patients With Non Hodgkin's Lymphoma Who Have Previously Received Rituximab

Lymphoma, Non-Hodgkin
Samsung Medical Center

Recruiting

Gemcitabine+ Capecitabine Vs Capecitabine in Curatively Resected Biliary Tract Cancer

Biliary Tract Cancer

Korea, Republic of
University of Southern California
Eli Lilly and Company

Completed

Capecitabine and Gemcitabine in Patients With Metastatic Colorectal Cancer

Colorectal Cancer | Colon Cancer

United States
Institute of Hematology & Blood Diseases Hospital...

Recruiting

Anti-CD38 Antibody Treating Pediatric Primary Immune Thrombocytopenia (ITP)

Immune Thrombocytopenia | Treatment

China
Institute of Hematology & Blood Diseases Hospital

Recruiting

Anti-CD38 Antibody Treating APS With Thrombocytopenia

Thrombocytopenia | Antiphospholipid Syndrome

China
Assistance Publique - Hôpitaux de Paris
Leeds Cancer Centre at St. James's University Hospital

Completed

Hematological Response in Patients With Paroxysmal Nocturnal Hemoglobinuria Treated With Anti-C5 Antibody: an External Control Arm Study for Iptacopan Use in Anti-C5 naïve Patients (APPEX)

Paroxysmal Nocturnal Hemoglobinuria

France
University of Nove de Julho

Recruiting

Evaluation of Antimicrobial Photodynamic Therapy and Minimal Intervention Associated With Deproteinization in Permanent Teeth With Molar Incisor Hypomineralization

Hypomineralization Molar Incisor

Brazil
Federal Research Institute of Pediatric Hematology...

Recruiting

Ex-vivo Primed Memory Donor Lymphocyte Infusion to Boost Anti-viral Immunity After T-cell Depleted HSCT

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Acute Lymphoblastic Leukemia, in Relapse | Non-hodgkin Lymphoma | High Risk Acute Myeloid Leukemia | High Risk Acute Lymphoblastic Leukemia | Acute Biphenotypic Leukemia in Relapse

Russian Federation
Tracon Pharmaceuticals Inc.

Completed

Open Label Phase 1 Dose Finding Study of TRC105 in Patients With Solid Cancer

Cancer | Neoplasm Metastasis

United States
National Cancer Institute (NCI)

Terminated

Combination Chemotherapy and Bevacizumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Colorectal Cancer

Stage IV Colon Cancer | Stage IV Rectal Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer | Adenocarcinoma of the Rectum | Stage III Colon Cancer | Stage III Rectal Cancer | Adenocarcinoma of the Colon

United States
Beijing 302 Hospital
Beijing GD Initiative Cell Therapy Technology Co., Ltd.; Chinese Academy of...

Not yet recruiting

Allogeneic Gamma-delta T Cells Combined With Targeted Therapy and Immunotherapy in a Phase 1 Clinical Trial of Hepatocellular Carcinoma Resistant to PD-1 Monoclonal Antibody

Hepatocellular Carcinoma
Sun Yat-sen University

Recruiting

PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma Patients

Recurrent Nasopharyngeal Carcinoma

China
Nanfang Hospital, Southern Medical University

Not yet recruiting

First-In-Human Study of Bispecific Antibody MR001 In Subjects With Advanced Solid Tumors

Advanced Solid Tumors

China
The First Affiliated Hospital of Soochow University
The First Affiliated Hospital with Nanjing Medical University; The Affiliated... and other collaborators

Recruiting

Vedolizumab, Anti-CD25 Antibody, Rapid Reduction of Glucocorticoids for SR-aGVHD With Gastrointestinal Involvement

Safety and Efficacy

China
National Cancer Institute (NCI)

Completed

Apolizumab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Recurrent Small Lymphocytic Lymphoma | Refractory Chronic Lymphocytic Leukemia | Stage III Small Lymphocytic Lymphoma | Stage IV Small Lymphocytic Lymphoma | Noncontiguous Stage II Small Lymphocytic Lymphoma

United States
National Cancer Institute (NCI)

Completed

Monoclonal Antibody Therapy in Treating Patients With Chronic Lymphocytic Leukemia, Lymphocytic Lymphoma, Acute Lymphoblastic Leukemia, or Acute Myeloid Leukemia

Recurrent Adult Acute Myeloid Leukemia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Marginal Zone Lymphoma | Splenic Marginal Zone Lymphoma | Recurrent Adult Acute Lymphoblastic Leukemia | Recurrent Small Lymphocytic... and other conditions

United States
M.D. Anderson Cancer Center
Eli Lilly and Company

Completed

Capecitabine, Gemcitabine, and Bevacizumab in Combination for Patients With Sarcomatoid Renal Cell Carcinoma

Kidney Cancer | Renal Cell Carcinoma

United States
Chinese PLA General Hospital

Recruiting

Study of Chidamide, Decitabine and Immune Checkpoint Inhibitors in R/R NHL and Advanced Solid Tumors

Advanced Solid Tumors | Relapsed/Refractory Non-Hodgkin Lymphoma

China
Shanghai Junshi Bioscience Co., Ltd.

Completed

A Single Dose Escalation Study of PCSK9 Inhibitor (JS002) in Health Subjects

Hypercholesterolemia

China
Vejle Hospital

Completed

A Phase II Study of Gemcitabine and Capecitabine for Treatment Resistant, Metastatic Colorectal Cancer (GemCaP)

Metastatic Colorectal Cancer

Denmark
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Suspended

A Study of First-line JS001 and Nab-paclitaxel Versus Palcelbo and Nab-Paclitaxel in Participants With Advanced Recurrent or Metastatic TNBC

Triple Negative Breast Cancer

China
Fudan University

Completed

The Comparison of XELOX and EOX in the First-line Treatment of Advanced Gastric Cancer

Gastric Cancer

China
Shanghai Celfuture Biotech Co., Ltd.

Not yet recruiting

A Study of Ametumumab in Combination With Anti-PD-1 Monoclonal Antibody and FOLFIRI in Patients With RAS Wild-type Advanced Colorectal Cancer

Colorectal Cancer

China
Qilu Hospital of Shandong University
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

Study of PD-1 Antibody and PARP Inhibitor in Extensive Stage Small Cell Lung Cancer

Small Cell Lung Cancer
Liang Peng
Guangzhou Virotech Pharmaceutical Co., Ltd.

Unknown

IIT Study of M1-c6v1 Combined With SHR-1210 and Apatinib in Patients With HCC

Advanced/Metastatic Hepatocellular Carcinoma
AIO-Studien-gGmbH
Amgen; WiSP Wissenschaftlicher Service Pharma GmbH

Completed

ECX + Panitumumab vs. ECX Alone in Locally Advanced Gastric Cancer or Cancer of the Gastroesophageal Junction (NEOPECX)

Stomach Neoplasms | Gastroesophageal Junction Neoplasms

Germany

Search clinical trials for: Anti-PD1 antibody, nimotuzumab and capecitabine

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United Arab Emirates

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations